Boyle, S M <br/><br/>
Donor-Derived Metastatic Melanoma and Checkpoint Inhibition.  [electronic resource] 

 -  Transplantation proceedings  Sep 2017 
 - 1551-1554 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article 
<br/><br/><label>ISSN: </label>1873-2623 
<br/><br/><label>Standard No.: </label>10.1016/j.transproceed.2017.06.007  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Allografts--pathology<br/>Antibodies, Monoclonal--therapeutic use<br/>Antineoplastic Agents--therapeutic use<br/>Checkpoint Kinase 1--antagonists & inhibitors<br/>Checkpoint Kinase 2--antagonists & inhibitors<br/>Humans<br/>Imidazoles--therapeutic use<br/>Kidney--pathology<br/>Kidney Neoplasms--drug therapy<br/>Kidney Transplantation--adverse effects<br/>Liver Neoplasms--drug therapy<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Nivolumab<br/>Oximes--therapeutic use<br/>Pyridones--therapeutic use<br/>Pyrimidinones--therapeutic use<br/>Tissue Donors